Heska (NASDAQ:HSKA) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.
Other equities research analysts have also issued research reports about the company. Raymond James Financial reaffirmed a “buy” rating on shares of Heska in a report on Monday, December 4th. Canaccord Genuity initiated coverage on Heska in a report on Thursday, October 5th. They issued a “buy” rating and a $115.00 price objective on the stock. B. Riley reaffirmed a “hold” rating and issued a $96.50 price objective on shares of Heska in a report on Friday, October 27th. Finally, Zacks Investment Research lowered Heska from a “buy” rating to a “hold” rating in a report on Wednesday, October 4th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have assigned a buy rating to the company’s stock. Heska currently has a consensus rating of “Hold” and a consensus target price of $113.30.
Heska (NASDAQ:HSKA) opened at $79.00 on Friday. The stock has a market capitalization of $572.26, a PE ratio of 41.36, a P/E/G ratio of 2.10 and a beta of 0.75. Heska has a 52-week low of $66.51 and a 52-week high of $115.00.
Heska (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.03. Heska had a return on equity of 15.35% and a net margin of 10.67%. The firm had revenue of $31.40 million for the quarter, compared to analysts’ expectations of $36.10 million. During the same quarter in the previous year, the firm posted $0.45 EPS. The firm’s revenue for the quarter was down 6.0% on a year-over-year basis. research analysts forecast that Heska will post 2.03 earnings per share for the current year.
In other Heska news, insider Michael J. Mcginley sold 7,826 shares of Heska stock in a transaction that occurred on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total value of $681,957.64. Following the sale, the insider now owns 106,771 shares of the company’s stock, valued at approximately $9,304,024.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 14.70% of the stock is currently owned by insiders.
Several large investors have recently made changes to their positions in the company. Neuberger Berman Group LLC boosted its stake in shares of Heska by 34.2% during the 3rd quarter. Neuberger Berman Group LLC now owns 603,469 shares of the medical research company’s stock worth $53,160,000 after acquiring an additional 153,895 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Heska by 31.7% during the 2nd quarter. Vanguard Group Inc. now owns 461,841 shares of the medical research company’s stock worth $47,141,000 after acquiring an additional 111,232 shares in the last quarter. State Street Corp boosted its stake in shares of Heska by 12.7% during the 2nd quarter. State Street Corp now owns 195,970 shares of the medical research company’s stock worth $19,998,000 after acquiring an additional 22,053 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in shares of Heska by 26.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 151,460 shares of the medical research company’s stock worth $13,342,000 after acquiring an additional 31,286 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Heska by 40.2% during the 3rd quarter. Wells Fargo & Company MN now owns 141,423 shares of the medical research company’s stock worth $12,458,000 after acquiring an additional 40,532 shares in the last quarter. 81.98% of the stock is currently owned by institutional investors and hedge funds.
COPYRIGHT VIOLATION WARNING: This article was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this article on another publication, it was copied illegally and republished in violation of United States and international copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2017/12/11/heska-hska-stock-rating-lowered-by-bidaskclub.html.
Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.
Receive News & Ratings for Heska Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska Corp and related companies with MarketBeat.com's FREE daily email newsletter.